Zacks: Analysts Anticipate Bellerophon Therapeutics Inc (BLPH) Will Announce Earnings of -$0.12 Per Share

Share on StockTwits

Wall Street brokerages expect Bellerophon Therapeutics Inc (NASDAQ:BLPH) to announce ($0.12) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Bellerophon Therapeutics’ earnings. Bellerophon Therapeutics posted earnings of ($0.22) per share during the same quarter last year, which would suggest a positive year over year growth rate of 45.5%. The firm is expected to report its next earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Bellerophon Therapeutics will report full-year earnings of ($0.40) per share for the current year. For the next fiscal year, analysts forecast that the company will report earnings of ($0.54) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of research analysts that follow Bellerophon Therapeutics.

Bellerophon Therapeutics (NASDAQ:BLPH) last announced its earnings results on Thursday, August 9th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.10).

A number of equities analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Bellerophon Therapeutics in a research report on Friday, May 11th. ValuEngine raised shares of Bellerophon Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, June 8th. Finally, Zacks Investment Research lowered shares of Bellerophon Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, August 6th.

BLPH stock traded down $0.02 on Thursday, reaching $0.83. 263,300 shares of the company were exchanged, compared to its average volume of 408,416. Bellerophon Therapeutics has a 12 month low of $0.47 and a 12 month high of $3.30. The firm has a market capitalization of $50.00 million, a P/E ratio of -0.92 and a beta of -0.84.

In related news, major shareholder Associates Iv L. P. Venrock bought 529,370 shares of the company’s stock in a transaction that occurred on Thursday, August 16th. The shares were acquired at an average price of $0.65 per share, with a total value of $344,090.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 57.80% of the company’s stock.

A hedge fund recently bought a new stake in Bellerophon Therapeutics stock. DRW Securities LLC purchased a new stake in Bellerophon Therapeutics Inc (NASDAQ:BLPH) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 70,000 shares of the biotechnology company’s stock, valued at approximately $146,000. DRW Securities LLC owned 0.12% of Bellerophon Therapeutics at the end of the most recent reporting period. 58.49% of the stock is currently owned by institutional investors.

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Bellerophon Therapeutics (NASDAQ:BLPH)

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply